The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago. Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets. As a better understanding of MMP biology and inhibitor pharmacokinetic properties emerged, it bec...
| الحاوية / القاعدة: | Cells |
|---|---|
| المؤلف الرئيسي: | |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
MDPI AG
2019-08-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mdpi.com/2073-4409/8/9/984 |